Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$16.56 USD

16.56
845,519

+0.74 (4.68%)

Updated Sep 13, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of -15.79% and 4.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 28.57% and 4.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 33% Upside in Hims & Hers Health, Inc. (HIMS): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Hims & Hers Health, Inc. (HIMS) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 18.18% and 11.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Hims & Hers Health, Inc. (HIMS) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health, Inc. (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 5% and 9.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sonendo, Inc. (SONX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Sonendo, Inc. (SONX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 21.5% in 4 Weeks, Here's Why Hims & Hers Health, Inc. (HIMS) Looks Ripe for a Turnaround

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Motus GI Holdings, Inc. (MOTS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Motus GI Holdings, Inc. (MOTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cigna (CI) to Announce Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Cigna's (CI) second-quarter results are likely to reflect higher pharmacy revenues and a growing customer base.

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nyxoah SA (NYXH) Stock Jumps 13.2%: Will It Continue to Soar?

by Zacks Equity Research

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 11.11% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -1.52% and 0.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of -16.22% and 14.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Hims & Hers Health, Inc. (HIMS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -10% and 11.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Q4 Earnings Beat Estimates

by Zacks Equity Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.50% and 2.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inspire Medical Systems (INSP) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 80.85% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

UBER Teams Up With Hims & Hers to Deliver Personal Care Products

by Zacks Equity Research

UBER expands its delivery network, partnering with Hims & Hers to offer on-demand delivery of personal wellness products to customers across the United States.

Here's Why Urban Outfitters (URBN) Stock Increases 20% YTD

by Zacks Equity Research

Urban Outfitters' (URBN) solid business initiatives including the FP Movement will continue boosting growth. Its merchandising strategy is also impressive.